The history of Viagra presents a complex picture for shareholders. While the initial introduction generated significant gains, the end of its patent opened the door to generic versions, dramatically diminishing sales. This poses a particular challenge for drug manufacturers banking on related blockbuster offerings, suggesting that a blind investmen

The legacy of Viagra, and its parent company copyright, presents a complex case study for investors. Originally a blockbuster drug, producing billions in sales , its intellectual property lapse created a deluge of generic competition , significantly impacting its position . While specific businesses may seek to capitalize on similar conditions , th